Fennec Pharmaceuticals Inc. – NASDAQ:FENC

Add to watchlist

$8.06

+1.84

+29.58%

Market closed

Open in about 12 hours

-2.66%

month

-2.66%

quarter

-46.10%

year

Market Cap	164.01M
Enterprise value	N/A

P/E	-9.92
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	152.85
Price/Book	-91.33
PEG ratio	0.28
EPS	0.08

Revenue	45.10M
EBITDA	6.34M
Income	2.76M
Revenue Q/Q	1406.47%
Revenue Y/Y	1304.34%

Profit margin	-2116.09%
Oper. margin	-2028.93%
Gross margin	94.4%
EBIT margin	-2028.93%
EBITDA margin	14.07%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Profit margin
Jun 2023	3.32M	-5.44M	-163.73%
Sep 2023	6.51M	-1.86M	-28.66%
Dec 2023	10.00M	-2.75M	-27.55%
Mar 2024	25.26M	12.83M	50.81%

Fennec Pharmaceuticals Financials Estimate

Q Y

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Analyst Estimates
Sep 2025	16.91M	6.13M	36.28%
Oct 2025	17.33M	3.51M	20.3%
Dec 2025	18.7M	5.85M	31.29%
Dec 2025	18.84M	4.65M	24.7%

Analysts Price target
Financials & Ratios estimates

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Earnings per share (EPS)
2024-03-21	-0.02	-0.1

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Debt to assets
Jun 2023	19437000	29.16M	150.04%
Sep 2023	19028000	29.55M	155.34%
Dec 2023	26726555	38.28M	143.26%
Mar 2024	69121672	66.11M	95.64%

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Cash Flow
Jun 2023	-3.94M	514K
Sep 2023	-2.73M	198.81K
Dec 2023	-4.97M	5.83M
Mar 2024	38.87M	-1.12M

Fennec Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Fennec Pharmaceuticals
Employees

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Employee count
Aug 2023	36
Sep 2023	36
Oct 2023	36
Nov 2023	36
Dec 2023	36
Jan 2024	36
Feb 2024	36
Mar 2024	36
Apr 2024	36
May 2024	29
Jun 2024	29
Jul 2024	29

Fennec Pharmaceuticals
Hedge Funds Holdings Q1 2023

11.08% -36.61%

of FENC is owned by hedge funds

29 -14

hedge funds hold FENC stock

2.91M -9.53M

shares is hold by hedge funds

FENC hedge funds holdings changes

Fennec Pharmaceuticals
Insider Trading

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	30000
Mar 2024	0	30064
Apr 2024	41667	352188
May 2024	0	2431
Jun 2024	0	2431
Jul 2024	0	3604
Aug 2024	0	2431
Sep 2024	0	2431
Oct 2024	0	3837
Nov 2024	0	2431
Dec 2024	0	8840

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	20 Dec 2024	RAYKOV ROSTY director director	Stock Options	25,000	$2.69	$67,250
Option	20 Dec 2024	RAYKOV ROSTY director director	Common shares	25,000	$2.69	$67,250
Sale	5 Dec 2024	RAYKOV ROSTY director director	Common shares	796	$6.04	$4,808
Sale	3 Dec 2024	RAYKOV ROSTY director director	Common shares	1,635	$6.13	$10,023
Option	2 Dec 2024	RALLIS CHRIS A director director	Common Shares	10,000	$2.69	$26,900
Option	2 Dec 2024	RALLIS CHRIS A director director	Common Shares	10,000	$2.69	$26,900
Sale	2 Dec 2024	RALLIS CHRIS A director director	Common Shares	6,409	$6.14	$39,351
Option	18 Nov 2024	ANDRADE ROBERT officer: CHIEF FI..	Stock Options	15,816	$2.45	$38,749
Option	18 Nov 2024	ANDRADE ROBERT officer: CHIEF FI..	Common shares	15,816	$2.45	$38,749
Sale	4 Nov 2024	RAYKOV ROSTY director director	Common shares	2,431	$4.31	$10,478

FENC insider trading transactions

Fennec Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF Filling date: 25 Jan 2022 Issue date: 26 May 2022	25 Jan 2022	26 May 2022
Grant	Grant Utility: Anhydrous sodium thiosulfate and formulations thereof Filling date: 28 Aug 2020 Issue date: 5 Apr 2022	28 Aug 2020	5 Apr 2022
Application	Application ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF Filling date: 28 Aug 2020 Issue date: 21 Jan 2021	28 Aug 2020	21 Jan 2021
Grant	Grant Utility: Anhydrous sodium thiosulfate and formulations thereof Filling date: 1 Jul 2019 Issue date: 6 Oct 2020	1 Jul 2019	6 Oct 2020
Application	Application FORMULATIONS OF ANHYDROUS SODIUM THIOSULFATE Filling date: 1 Jul 2019 Issue date: 23 Jan 2020	1 Jul 2019	23 Jan 2020
Application	Application ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF Filling date: 1 Jul 2019 Issue date: 9 Jan 2020	1 Jul 2019	9 Jan 2020

FENC patents

Fennec Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 14 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 21 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 6 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 6 Aug 2023	Q2 2023 Earnings Call Transcript

FENC earnings call transcripts

Fennec Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Rostislav Raykov (1976) Chief Executive Officer & Director	49	$430,000
Ms. Shubh Goel (1974) Chief Commercial Officer	51	$360,000
Mr. Robert C. Andrade (1975) Chief Financial Officer	50	$311,750

Fennec Pharmaceuticals
Latest News

Friday, 20 December 2024
06:16	Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales	globenewswire.com
Thursday, 19 December 2024
06:13	Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management	globenewswire.com
Thursday, 12 December 2024
07:01	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference	globenewswire.com
Wednesday, 13 November 2024
06:27	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference	globenewswire.com
Saturday, 9 November 2024
22:33	Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 7 November 2024
08:26	Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates	zacks.com
06:13	Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Thursday, 31 October 2024
06:23	Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024	globenewswire.com
Monday, 28 October 2024
11:05	Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for	zacks.com
06:23	Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth	globenewswire.com
Thursday, 5 September 2024
06:56	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences	globenewswire.com
Tuesday, 13 August 2024
14:20	Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript	seekingalpha.com
08:26	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates	zacks.com
06:05	Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Tuesday, 6 August 2024
16:31	Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024	globenewswire.com
Monday, 5 August 2024
06:26	Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director	globenewswire.com
Monday, 29 July 2024
06:15	3 Dirt-Cheap Stocks Under $10 That Could EXPLODE!	investorplace.com
Monday, 1 July 2024
06:00	Fennec Pharmaceuticals Announces Management Change	globenewswire.com
Tuesday, 25 June 2024
16:35	Fennec Announces Results of Annual Meeting	globenewswire.com
Tuesday, 14 May 2024
13:15	Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript	seekingalpha.com
08:16	Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates	Zacks Investment Research
Tuesday, 7 May 2024
18:15	Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024	GlobeNewsWire
Thursday, 21 March 2024
08:16	Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 19 March 2024
11:16	Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up	Zacks Investment Research
09:51	Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable	Zacks Investment Research
06:01	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024	GlobeNewsWire
Wednesday, 13 March 2024
10:56	Wall Street Analysts See a 64.61% Upside in Adherex Technologies Inc. (FENC): Can the Stock Really Move This High?	Zacks Investment Research
Wednesday, 6 March 2024
20:39	Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price	Seeking Alpha
Thursday, 21 December 2023
10:32	Recent Price Trend in Adherex Technologies Inc. (FENC) is Your Friend, Here's Why	Zacks Investment Research
Monday, 27 November 2023
11:17	Wall Street Analysts Think Adherex Technologies Inc. (FENC) Could Surge 81%: Read This Before Placing a Bet	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 9 Nov 2023

Fennec Pharmaceuticals Expands Possible TAM Significantly
Seeking Alpha 26 Apr 2023

Fennec Pharmaceuticals: Undervalued, Near-Cash-Flow-Positive, Possible Buyout Candidate
Seeking Alpha 5 Apr 2023

Fennec Pharmaceuticals Gains Momentum With Industry Endorsements
Seeking Alpha 16 Jan 2023

Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale
Seeking Alpha 24 Oct 2022

Fennec: Pedmark Approval Can Help Minimize Chemo-Induced Hearing Loss In Pediatric Cancer Patients
Seeking Alpha 23 Aug 2022

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Seeking Alpha 22 Jul 2022

Fennec Pharmaceuticals - Biopharma
Seeking Alpha 29 Oct 2021

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Seeking Alpha 24 Jun 2021

Fennec Pharmaceuticals: The PEDMARK NDA Has Been Accepted, We Remain Bullish On The November PDUFA Catalyst
Seeking Alpha 12 May 2021

scPharmaceuticals: The Third Time's A Charm

Frequently Asked Questions (FAQ)

What's the price of Fennec Pharmaceuticals stock today?

One share of Fennec Pharmaceuticals stock can currently be purchased for approximately $8.06.
When is Fennec Pharmaceuticals's next earnings date?

Unfortunately, Fennec Pharmaceuticals's (FENC) next earnings date is currently unknown.
Does Fennec Pharmaceuticals pay dividends?

No, Fennec Pharmaceuticals does not pay dividends.
How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals has a market capitalization of 164.01M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1284.5% to 21.25M US dollars. Fennec Pharmaceuticals made a loss 16.05M US dollars in net income (profit) last year or -$0.1 on an earnings per share basis.
What is Fennec Pharmaceuticals's stock symbol?

Fennec Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "FENC".
What is Fennec Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Fennec Pharmaceuticals?

Shares of Fennec Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Fennec Pharmaceuticals's key executives?
Fennec Pharmaceuticals's management team includes the following people:
- Mr. Rostislav Raykov Chief Executive Officer & Director(age: 49, pay: $430,000)
- Ms. Shubh Goel Chief Commercial Officer(age: 51, pay: $360,000)
- Mr. Robert C. Andrade Chief Financial Officer(age: 50, pay: $311,750)
How many employees does Fennec Pharmaceuticals have?

As Jul 2024, Fennec Pharmaceuticals employs 29 workers, which is 19% less then previous quarter.
When Fennec Pharmaceuticals went public?

Fennec Pharmaceuticals Inc. is publicly traded company for more then 8 years since IPO on 15 Sep 2017.
What is Fennec Pharmaceuticals's official website?

The official website for Fennec Pharmaceuticals is fennecpharma.com.
Where are Fennec Pharmaceuticals's headquarters?

Fennec Pharmaceuticals is headquartered at 68 TW Alexander Drive, Research Triangle Park, NC.
How can i contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals's mailing address is 68 TW Alexander Drive, Research Triangle Park, NC and company can be reached via phone at +91 96364530.

Fennec Pharmaceuticals Inc.

fennecpharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

+91 96364530

68 TW Alexander Drive
Research Triangle Park, NC 27709

CIK: 0001211583
ISIN: CA31447P1009
CUSIP: 31447P100